Fusions of E-twenty-six (Ets) transcription factor genes with androgen-responsive genes [2], are present in 50-70% of prostate-specific antigen (PSA) screened prostate cancers from populations of predominantly European descent. The gene discussed is KLK3; the disease is prostate carcinoma.